BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Real-World Study Reports 91% of Tinnitus Patients Improved With Neuromod's FDA-Approved Device

by BiopharmaTrend   •   May 26, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

A real-world study published in Nature Communications Medicine has reported that 91.5 percent of tinnitus patients experienced a clinically meaningful reduction in symptoms after 12 weeks of treatment using Lenire, a non-invasive, FDA-approved neuromodulation device. The study analyzed 220 patients treated at the Alaska Hearing and Tinnitus Center and represents one of the largest real-world assessments of tinnitus therapy published to date.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Lenire delivers bimodal stimulation (pairing sound through headphones with mild electrical pulses to the tongue) and is prescribed for at-home use under audiologist supervision. Interim results showed 78 percent of patients had symptom relief by six weeks, with further improvement by the 12-week mark. The outcomes mirror results from Neuromod Devices’ TENT-A3 trial, which supported the device’s FDA De Novo authorization in 2023.

The study adds to a growing base of real-world evidence compiled by Neuromod across thousands of patients, and is expected to be followed by additional publications. Lenire is currently available in the US, Europe, and through the Department of Veterans Affairs.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.